Article Per Year (5 Year)
p-Index From 2021 - 2026
0.778
P-Index
This Author published in this journals
All Journal JURNAL PHOTON Jurnal Farmasi Indonesia AS-SHIHA: JURNAL KESEHATAN Journal Of Pharmacy
Hari, Dewi Gulyla
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Dentistry Health Professions Medicine & Pharmacology Nursing Physics Public Health Veterinary

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Desain Primer PCR Sebagai Biomarker COVID-19 Strain Terbaru Yang Di Identifikasi Di Januari 2021 Herli, Muhammad Azhari; Hari, Dewi Gulyla; Rahmawati, Ayu
Photon: Jurnal Sain dan Kesehatan Vol. 11 No. 2 (2021): Jurnal Photon
Publisher : LPPM Universitas Muhammadiyah Riau

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37859/jp.v11i2.3645

Abstract

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by Severe Acute Respiratory Syndrome Corona Virus 2 (SARS CoV-2). The disease first spread in Wuhan, Hubei Province, China in December 2019. SARS-CoV-2 is highly contagious and has grown rapidly around the world since its discovery. Until January 2021, a total of 101,406,059 confirmed cases of SARS-CoV-2 infection worldwide with a death toll of 2,191,898 and still growing. Diagnosis of COVID-19 is carried out in two common ways, namely a rapid test and PCR (polymerase chain reaction). This study aims to design a PCR primer for the latest COVID-19 strain isolated in January 2021 with the insilico method (computer simulation) so that the primer used as a COVID-19 biomarker is fast and accurate. The results of this study obtained 10 of the best primers from the latest COVID-19 strains with codes MW454767, MW454771, MW460582, MW454660 which were identified on 11 Jan 2021.
Cytotoxic Activity Testing The Extract of Leaves and Yellow Sirsak Fruit (Annona montana) using Method Brine Shrimp Lethality Test (BSLT) Rahmawati, Noveri; Hari, Dewi Gulyla; Tri Nova Lovena; Nurdina Putri; Rahma Dona; Rahma Cintya Faiza; Amini, Rahmi
The Journal Of Pharmacy Vol. 2 No. 2 (2025): Journal Of Pharmacy UMRI
Publisher : LPPM, Universitas Muhammadiyah Riau

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

The yellow sirsak plant (Annona montana) is an annonaceae family which has been used by the community as traditional medicine properties such as treating diarrhea, vitamin C deficiency and treating boils. This study aims to determine the cytotoxic activity of the larvae of Artemia salina Leach shrimp by using the BSLT method after giving extracts from the leaves and fruit of yellow sirsak (Annona montana). The results showed that the LC50 value of the n- hexane extract of yellow sirsak leaves was 45,84 µg/mL, the ethyl acetate extract of yellow sirsak leaves was 26,44 µg/mL and the ethanol extract of yellow sirsak leaves was 13,99 µg/mL. The n-hexane extract of yellow sirsak fruit was 31,46 µg/mL, the ethyl acetate extract was 40,45 µg/mL and the ethanol extract of the yellow sirsak fruit was 19,84 µg/mL. The mixture of n-hexane leaves and yellow sirsak fruit was 29,91 µg/mL, the ethyl acetate extract mixture of yellow sirsak leaves and fruit was 21,71 µg/mL and the mixture of ethanol extract and yellow sirsak fruit was 14,75 µg/mL. Based on the research results, it can be concluded that the ethanol extract of yellow sirsak leaves shows the most active cytotoxic activity with an LC50 value of 13,99 µg/mL.
Detection of Gene E6 HPV 18 With Real Time PCR (Polymerase Chain Reaction) Using Isolated Samples of Uterine Cancer Patients in Riau Province Hari, Dewi Gulyla
As-Shiha: Jurnal Kesehatan Vol. 1 No. 2 (2021): As-Shiha: Jurnal Kesehatan
Publisher : Fakultas MIPA dan Kesehatan, Universitas Muhammadiyah Riau

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

One indication that there has been malignancy in cervical lesions due to exposure to high-risk hpv types such as HPV 16 and 18 is the detection of oncogene DNA in the cervical tissue of cancer patients. The oncogenes are the E6 and E7 genes. Previous research data showed evidence that the prognosis of HPV 18 is more massive than that of other high-risk HPV types such as HPV 16. Thus, the effort to detect the E6 gene from biopsy samples of patients suspected of cervical cancer is the right and effective step in order to establish an accurate diagnosis of cervical cancer itself, especially caused by HPV 18.
17-2 Analisis Perbandingan Biaya Riil dan Tarif Ina-Cbg’s pada Pasien Rawat Jalan Onkologi dengan Terapi Morfin Sulfat (Mst) di RSUD Arifin Achmad Provinsi Riau Meirita, Efilia; Endri, Novtafia; Hari, Dewi Gulyla; Lifiani, Rialita
JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X Vol. 17 No. 2 (2025): Jurnal Farmasi Indonesia
Publisher : Pengurus Pusat Ikatan Apoteker Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Health service financing through the INA-CBG's (Indonesia Case-Based Groups) system aims for efficiency and transparency in the National Health Insurance (JKN) system. However, in practice, there are often discrepancies between INA-CBG's rates and the real costs incurred by health facilities, especially in oncology patients with Morphine Sulfate (MST) therapy. This study aims to analyze the comparison of real costs and INA-CBG's tariffs for oncology outpatients with morphine sulfate therapy (MST) at RSUD Arifin Achmad Riau Province. This study used descriptive observational research method with retrospective data collection obtained from medical records of oncology outpatients who received Morphine Sulfate (MST) therapy 10 mg and 15 mg tablets during the period January-March 2024. The data were analyzed by comparing the real costs incurred by the hospital with the rates paid by BPJS through the INA-CBG's system and the Mann-Whitney U test was performed. The results of the analysis showed that there was a significant difference between real costs and INA-CBG's tariffs. The average real cost of drugs (MST) was higher than the INA-CBG's tariff. The real cost of drugs that exceeded the INA-CBG's tariff amounted to 481 people, with a total cost difference (loss) of IDR 218,155,324. There was a difference between real costs and INA-CBG's rates (p = .047) and INA-CBG's rates (p = .113).
Co-Authors Amini, Rahmi AYU RAHMAWATI Herli, Muhammad Azhari Lifiani, Rialita Meirita, Efilia Noveri Rahmawati Novtafia Endri Nurdina Putri Rahma Cintya Faiza Rahma Dona Tri Nova Lovena